miRNA Biomarkers in Multiple Sclerosis

Multiple Sclerosis (MS) characterized by demyelination and axonal degeneration is a chronic inflammatory disease of the central nervous system (CNS). Recent studies have shown that dysregulated miRNAs alter immune responses, so they may have roles basis on various genetic diseases such as MS and may be potential targets for biomarkers and new therapeutic approaches. In this study, we evaluated the dysregulation of miRNA expression levels at MS and MS stages. We also discussed the potential of these miRNAs to be biomarkers and/or therapeutic targets in MS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Biomarker Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Epigenetic Immune System Diseases Nervous System Diseases miRNA

Age range

25 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The age of 25 years and above
at least one Central Nervous System (CNS) demyelination event

Exclusion criteria

with genetic diseases, hypertension, head trauma, neuropsychiatric disease, diabetes mellitus, hypertension, cardiac failure, hepatic failure, renal failure, Thalassemia, Sickle cell disease, iron deficiency, and B12 deficiency

Treatment and study plan

miRNA

Genetic

miRNA effect on Multiple sclerosis pathology

Primary outcomes

miRNA expression

Time frame: intraoperative

peripheral blood miRNA expressions

Sponsors and collaborators

Lead sponsor

University of Gaziantep

Other

Registry information

Official study title

The Potential Candidate miRNA Biomarkers in Multiple Sclerosis

Important dates

Study start: 2015
Primary completion: 2017
Study completion: 2017
First posted: Feb 26, 2021
Registry last updated: Feb 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed